-
Tytuł:
-
A new Korean Research Investment for Global Health Technology (RIGHT) Fund to advance innovative neglected-disease technologies.
-
Autorzy:
-
Hotez PJ; RIGHT Fund, Seoul, Republic of Korea.; Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
Bush K; RIGHT Fund, Seoul, Republic of Korea.; Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Oswald A; RIGHT Fund, Seoul, Republic of Korea.; Life Sciences Partnerships, Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Rockman G; RIGHT Fund, Seoul, Republic of Korea.; Adjuvant Capital, New York, New York, United States of America.
Lim IT; RIGHT Fund, Seoul, Republic of Korea.; Korean Ministry of Health and Welfare (MOHW), Sejong, Republic of Korea.
Jee Y; RIGHT Fund, Seoul, Republic of Korea.; Center for Infectious Disease Research at the National Institute of Health, Korea Centers for Disease Control & Prevention (CDC), Osong, Republic of Korea.
Moon CJ; RIGHT Fund, Seoul, Republic of Korea.
Kim JH; International Vaccine Institute (IVI), Seoul, Republic of Korea.
Kim Y; RIGHT Fund, Seoul, Republic of Korea.
-
Źródło:
-
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2020 Sep 03; Vol. 14 (9), pp. e0007956. Date of Electronic Publication: 2020 Sep 03 (Print Publication: 2020).
-
Typ publikacji:
-
Editorial
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: San Francisco, CA : Public Library of Science
-
MeSH Terms:
-
Biomedical Technology/*economics
Neglected Diseases/*prevention & control
Biomedical Technology/organization & administration ; Biomedical Technology/trends ; Financial Management ; Global Health/economics ; Humans ; Neglected Diseases/economics ; Neglected Diseases/epidemiology ; Republic of Korea/epidemiology
-
References:
-
Korean J Parasitol. 2006 Sep;44(3):177-85. (PMID: 16969055)
Lancet Glob Health. 2013 Oct;1(4):e184-5. (PMID: 25104343)
PLoS Biol. 2017 Nov 9;15(11):e2004186. (PMID: 29121043)
-
Entry Date(s):
-
Date Created: 20200904 Date Completed: 20201027 Latest Revision: 20201027
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC7470318
-
DOI:
-
10.1371/journal.pntd.0007956
-
PMID:
-
32881862
-
In 2018, the government of the Republic of Korea (ROK), South Korean life science companies, and a group of international funders led by the Bill & Melinda Gates Foundation launched a new and innovative funding agency to support neglected-disease research and development (R&D). The new venture is known as the Research Investment for Global Health Technology (RIGHT) Fund.
Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: GR has an interest in the financial success of two public health impact investment funds, Global Health Investment Fund I, LLC, and Adjuvant Global Health Technology Fund, LP, where he holds investment advisory roles. Both organizations may benefit from grant funding provided by the organizations described in this publication. Equally, both organizations may be disadvantaged by grant funding provided flowing to competing technologies.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
